60 Degrees Pharmaceuticals, Inc. (SXTP)

NASDAQ: SXTP · Real-Time Price · USD

0.450

-0.023 (-4.88%)

At close: Feb 21, 2025, 4:00 PM

0.440

-0.010 (-2.22%)

After-hours: Feb 21, 2025, 7:48 PM EST

SXTP Employees

60 Degrees Pharmaceuticals had 3 employees as of December 31, 2023. The number of employees increased by 1 or 50.00% compared to the previous year.

Employees

3

Change (1Y)

1

Growth (1Y)

50.00%

Revenue / Employee

$154,204

Profits / Employee

-$2,721,716

Market Cap

3.31M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	3	1	50.00%
Dec 31, 2022	2	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	440,000
Johnson & Johnson	131,900
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	72,000

Employee Rankings

SXTP News

1 day ago - 60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
2 days ago - 60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split - GlobeNewsWire
11 days ago - Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF® - GlobeNewsWire
15 days ago - 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
17 days ago - 60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
22 days ago - 60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
25 days ago - 60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - GlobeNewsWire
6 weeks ago - 60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis - GlobeNewsWire